Febuxostat (Uloric), A New Treatment Option for Gout
Year: 2010
Type: article
Abstract: Gout is a rheumatic condition resulting from the deposition of monosodium urate crystals (tophi) in the joints or soft tissues. It is usually associated with elevated serum uric acid levels (greater than 7 mg/dL). The diagnosis is based on uric acid crystals found in the joints, tissues, or body fluids, as well as on gouty attacks or flares characterized by intense pain, swelling, redness, and heat.1–4 The peak incidence of gout occurs between 30 and 50 years of age. Approximately 1% to 2% of Americans are affected, with an equal prevalence in men and women; however, men are more likely to have elevated serum uric acid levels (hyperuricemia).2,4,5
Hyperuricemia results from the accumulation of uric acid, the end product of purine metabolism, which possesses no physiological role.2,6 It has been associated with a high-purine diet (i.e., meats, seafood), alcohol use, diuretic therapy, reduced renal clearance, hypertriglyceridemia, and diabetes mellitus.2,6,7 Non-steroidal anti-inflammatory medications (NSAIDs), colchicine, corticosteroids, and analgesics are commonly used in the acute treatment of gout. Goals of therapy include controlling acute attacks, preventing recurrent attacks, and preventing or reversing complications.6,8
Chronic management of gout may include the long-term use of urate-lowering agents after an attack is treated and prophylactic therapy has been considered. Antihyperuricemic therapy is indicated in patients who have had two or more gouty attacks per year, tophaceous gout, erosive arthritis on radiographs, or uric acid kidney disease.9,10 In most patients, a serum uric acid level of below 6 mg/dL is the initial target for therapy. Urate-lowering agents should be started after the complete resolution of a gouty attack because a rapid decrease in serum urate levels sometimes exacerbates a subsequent attack.2,8
Underexcretion of uric acid is responsible for gout in approximately 90% of patients; therefore, uricosuric agents should be used in most patients after ongoing urate deposition has been confirmed and attempts to correct or reverse other causes of hyperuricemia have been made.6,7,11 Inhibitors of uric acid synthesis are also used, particularly for patients who produce excessive amounts of urate (more than 800 mg in 24 hours).8
Allopurinol (Zyloprim, Prometheus), a potent purine xanthine oxidase (XO) inhibitor, is the most commonly used drug in the treatment of hyperuricemia. Until recently, it was the only available inhibitor of uric acid synthesis. In February 2009, the FDA approved febuxostat (Uloric, Takeda Pharmaceutics America), a structurally unrelated non-purine XO inhibitor, for the chronic management of hyperuricemia in patients with gout.12,13
Source: PubMed Central
Authors: Carmela Avena-Woods, Olga Hilas
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1173313548
